Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSING SCHEDULES OF PF-00299804 IN PATIENTS WITH ADVANCED MALIGNANT SOLID TUMORS

The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.

Inclusion Criteria:

• Malignant solid tumor for which there is no currently approved treatment
• Adequate bone marrow, liver, cardiac, and kidney function

Exclusion Criteria:

• Cardiac disease
• Anticancer therapy within 4-6 weeks (depending on therapy)
• Pregnant or breast-feeding